Skip to main content
main-content

Diabetes complications and comorbidities

Non-alcoholic fatty liver disease

05-24-2019 | Non-alcoholic fatty liver disease | News

Diabetes patients at high risk of serious NAFLD outcomes

People with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis are at particularly high risk for progression to cirrhosis or hepatocellular carcinoma if they have diabetes, say researchers.

12-05-2018 | Non-alcoholic fatty liver disease | Article

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Lonardo A, Lugari S, Ballestri S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1266-0

03-20-2018 | Diet | News

DiRECT: Effects on insulin and liver fat revealed

Researchers from the DiRECT trial have reported large positive effects on liver fat and insulin secretion among people who achieved type 2 diabetes remission in response to a very-low-calorie diet.

02-07-2018 | Risk factors | Highlight | News

‘Subtle’ metabolic derangement seen decades before diabetes diagnosis

Research shows that changes in markers of the metabolic syndrome and fatty liver disease are present more than 20 years before people receive a diagnosis of type 2 diabetes.

12-29-2017 | Nephropathy | Review | Article

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Nat Rev Endocrinol 2017; 14: 99–114. doi: 10.1038/nrendo.2017.173

09-20-2017 | Non-alcoholic fatty liver disease | EASD 2017 | News

NAFLD: The associated risks and potential treatments

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

09-13-2017 | Diet | EASD 2017 | News

Hypocaloric low-fat and low-carbohydrate diets beneficial in type 2 diabetes

Results of a randomized trial suggest that patients with type 2 diabetes experience metabolic benefits from a hypocaloric diet regardless of whether it is low in fat or low in carbohydrate content.

08-03-2017 | Ipragliflozin | News

Ipragliflozin and pioglitazone ‘equally beneficial’ for type 2 diabetes with NAFLD

Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.

Image Credits